Psychemedics Corporation (PMDI)

Market Cap	15.25M +8.5%
Revenue (ttm)	19.69M -10.9%
Net Income	-1.86M
EPS	-0.32
Shares Out	6.12M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	2.490
Previous Close	2.490
Day's Range	2.490 - 2.490
52-Week Range	1.330 - 2.700
Beta	0.74
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Psychemedics

Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. The company provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; syntheti...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1986
• Employees: 101
• Stock Exchange: OTCMKTS
• Ticker Symbol: PMDI

Financial Performance

In 2024, Psychemedics's revenue was $19.69 million, a decrease of -10.92% compared to the previous year's $22.10 million. Losses were -$1.86 million, -55.20% less than in 2023.

Data Sources: S&P Global Market Intelligence and Alpha Vantage

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Alpha Vantage.

Last checked:

Oct 22, 2026

Data Sources Report a data error